c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, agenetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.

Biotechnology

Pharmaceutical

c-LEcta GmbH

Dr. Marc Struhalla

Kamila Rzeznicka

Patrick Hapke

Carsten Fietz

Nicole Albrecht

Dr. Michael Dirkmann

Christine Merten

Pierre Aldag

Tjebbe van der Meer

Heike Kutschke

Arlett Merkel

Raphael Gübeli

Andreas Vogel

Arnd Knoll

Mathias Bell

Andreas Buthe

The Biopharma Innovation Team at c-LEcta GmbH is responsible for spearheading the development and commercialization of innovative enzyme-based solutions tailored for the pharmaceutical industry. This team collaborates closely with industry partners to identify and address market needs, ensuring the creation of highly effective and application-oriented enzyme variants that assist in pharmaceutical manufacturing and bioprocesses.

Biopharma Innovation Team

Research and Development

Leadership Team

Sales and Business Development

Biopharma Innovation Team

About

Team members

Other teams at c-LEcta GmbH

Research and Development

Leadership Team

Sales and Business Development